Takeda Pharmaceutical Co. $TAK Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 37.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 247,529 shares of the company’s stock after acquiring an additional 67,770 shares during the quarter. JPMorgan Chase & Co.’s holdings in Takeda Pharmaceutical were worth $3,624,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in TAK. Twin Peaks Wealth Advisors LLC acquired a new position in Takeda Pharmaceutical in the second quarter valued at approximately $28,000. True Wealth Design LLC boosted its holdings in shares of Takeda Pharmaceutical by 1,262.3% in the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock valued at $40,000 after buying an additional 2,512 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares during the last quarter. Advisory Services Network LLC purchased a new position in shares of Takeda Pharmaceutical in the 3rd quarter valued at $74,000. Finally, Farther Finance Advisors LLC raised its stake in Takeda Pharmaceutical by 24.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company’s stock worth $102,000 after acquiring an additional 1,378 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on TAK shares. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Wall Street Zen downgraded Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 21st. Morgan Stanley initiated coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an “overweight” rating for the company. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Down 0.1%

NYSE TAK opened at $18.73 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19. The firm has a market cap of $59.59 billion, a PE ratio of 78.02 and a beta of -0.01. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The firm’s fifty day moving average is $18.07 and its two-hundred day moving average is $15.87.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Friday, January 30th. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.07). The business had revenue of $7.60 billion for the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. Analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.